Charlotte Hubbert

Dr. Charlotte Hubbert joined Lineage as Vice President of Corporate Development in April 2024. Dr. Hubbert has over fifteen years basic science research background and over fifteen years biotech venture investment experience across a broad range of sectors, therapeutic modalities, and stages. She has a proven ability to combine deep scientific expertise and business development acumen to identify innovative opportunities to drive both returns and impact. She is also a Strategic Director at Madrona Venture Group, where she advises their growing A/ML-driven life science portfolio and serves on the Board of Directors of the Beckman Research Institute at the City of Hope.

Before joining Lineage, she was on the leadership team for Business Development & Strategic Alliances at NanoString Technologies. Previous to NanoString, Dr. Hubbert was Partner and head of Gates Foundation Venture Capital, a $500 million initiative at the Bill and Melinda Gates Foundation Strategic Investment Fund, where she oversaw investing in innovative technologies that supported the foundation’s programs in global health and agriculture. Notably, she led investments and served on the board of directors of Synlogic (Nasdaq: SYBX), Sera Prognostics, Lodo Therapeutics, Agtech Accelerator, Vedanta, and Vir Biotechnology (Nasdaq: VIR). Prior to joining the Bill and Melinda Gates Foundation Strategic Investment Fund. Dr. Hubbert was a vice president at H.I.G. BioVentures, investing broadly in healthcare. She began her career in early-stage biotech, investing at Accelerator Corporation, where she was part of the founding team.

Dr. Hubbert earned a B.S. in microbiology from the University of Washington and a Ph.D. in cancer biology from Duke University for which she received the prestigious Harold Weintraub Award. She did her post-doctoral work in stem cells and regenerative medicine at the Institute for Stem Cells and Regenerative Medicine at the University of Washington. Dr. Hubbert is a member of the Kauffman Society of Fellows and is a Fierce Woman in Biopharma awardee which recognizes top executives in Biopharma. She previously served on the Board of Directors of Life Science Washington, and the steering committees of the Fred Hutch Cancer Institute’s Evergreen Fund, University of Washington Innovation Roundtable and Columbia University Lab-to-Market initiative.

‍